EuroAPI Header EuroAPI Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of RS Oncology.

    Client Virtual Booth

    RS ONCOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    RS Oncology
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Cambridge, MA 02142
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.rsoncology.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rs-oncology/
    Twitter
    Twitter
    https://twitter.com/RSOncologyLLC?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    RS Oncology Reports Positive Phase 1 Data for RSO-021 in Malignant Pleural Mesothelioma

    Details:

    RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to PRX3. It is being evaluated for the treatment of malignant pleural mesothelioma.


    Lead Product(s): Thiostrepton

    Therapeutic Area: Oncology Product Name: RSO-021

    Highest Development Status: Phase I/ Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 03, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    RS Oncology Announces First Patient Dosed in Phase 2 Clinical Study (MITOPE) Investigating RSO-021 for the Treatment of Malignant Pleural Mesothelioma a...

    Details:

    RSO-021 (thiostrepton) is a novel small molecule, that irreversibly binds to mitochondrial peroxiredoxin 3 (PRX3). It is being evaluated in phase 2 clinical trials for the treatment of malignant pleural mesothelioma and metastatic disease to the lung.


    Lead Product(s): Thiostrepton

    Therapeutic Area: Oncology Product Name: RSO-021

    Highest Development Status: Phase IIProduct Type: Peptide

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 01, 2024

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    aspen-api-m-2024-08-19

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search